Edition:
India

Kaken Pharmaceutical Co Ltd (4521.T)

4521.T on Tokyo Stock Exchange

6,390JPY
20 Apr 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
¥6,390
Open
¥6,370
Day's High
¥6,440
Day's Low
¥6,370
Volume
73,500
Avg. Vol
133,245
52-wk High
¥6,970
52-wk Low
¥5,430

Latest Key Developments (Source: Significant Developments)

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Kaken Pharmaceutical gets domestic manufacture and marketing approval for periodontium regeneration medicine
Wednesday, 28 Sep 2016 

Kaken Pharmaceutical Co Ltd <4521.T>:Says it received domestic manufacture and marketing approval for a periodontium regeneration medicine.  Full Article

Kaken Pharmaceutical to co-promote allergic medicine with Kyorin Holdings unit
Monday, 11 Jul 2016 

Kaken Pharmaceutical Co Ltd <4521.T>:Says the company entered into basic agreement with Kyorin Holdings Inc <4569.T>'s unit on co-promotion of an allergic medicine, whose exclusive sales right is owned by the Kyorin Holdings's unit.  Full Article

Kaken Pharmaceutical appoints ARK MEIJI AUDIT & Co. as auditor
Friday, 1 Jul 2016 

Kaken Pharmaceutical Co Ltd <4521.T>:Says it appointed ARK MEIJI AUDIT & Co. as auditor, effective July 1.  Full Article

Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea
Tuesday, 31 May 2016 

Kaken Pharmaceutical Co Ltd <4521.T> : Says Kaken Pharmaceutical <4521.T> and A Korea-based firm Dong-A ST Co Ltd <170900.KS> concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” in Korea .Says according to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.  Full Article

BRIEF-Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment

* ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR PSORIASIS